We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04369365
Recruitment Status : Completed
First Posted : April 30, 2020
Last Update Posted : April 7, 2022
Sponsor:
Information provided by (Responsible Party):
Prof. Dr. Matthias Preusser, Medical University of Vienna

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Prophylactic treatment in cancer patients undergoing antineoplastic therapy during the COVID-19 pandemic.

Condition or disease Intervention/treatment Phase
COVID Drug: Azithromycin 500 milligram (mg) oral Tablet Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic
Actual Study Start Date : April 27, 2020
Actual Primary Completion Date : June 15, 2021
Actual Study Completion Date : June 15, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm A: Azithromycin
weekly oral azithromycin 1500mg for a maximum of 8 weeks
 Drug: Azithromycin 500 milligram (mg) oral Tablet
weekly oral use
Placebo Comparator: Arm B: Placebo
weekly oral placebo for a maximum of 8 weeks
 Drug: Placebo
weekly oral use


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections [ Time Frame: 12 weeks after initiation of therapy ]
    assessed by positive polymerase chain reaction (PCR) from routine nasal swabs (performed every 28 days)


Secondary Outcome Measures :
  1. Number of severe COVID-19 cases [ Time Frame: 12 weeks after initiation of therapy ]
    defined as combined endpoint of hospitalization rate or death

  2. Severity of COVID-19 cases [ Time Frame: 12 weeks after initiation of therapy ]
    grading as outlined by the world health organization (WHO)

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 12 weeks after initiation of therapy ]
    significant clinical and laboratory abnormalities according to CTCAE criteria

  4. Number of viral and bacterial infections [ Time Frame: 12 weeks after initiation of therapy ]
    other than COVID-19

  5. Number of participants with azithromycin-resistant bacterial strains in nasal swabs test [ Time Frame: 12 weeks after initiation of therapy ]
    Development of azithromycin-resistant bacterial strains as assessed by nasal swabs test


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed cancer diagnosis
  • Ongoing systemic antineoplastic treatment irrespective of application route
  • Age ≥ 18 years
  • Life expectancy of at least 3 months
  • Adequate renal, cardiac and liver function
  • Corrected QT time (QTc) ≤ 450 ms
  • Eastern Cooperative Oncology Group (ECOG) performance status of < 3
  • Capable of understanding the study and giving informed consent
  • Negative COVID-19 test at study entry as measured by routine testing

Exclusion Criteria:

  • Use of any investigational agent within 28 days prior to study start
  • Patients with active opportunistic infections
  • Pregnant or lactating women
  • Women of childbearing potential and male subjects not willing to use adequate contraception methods during the study period
  • Hypersensitivity to azithromycin or other macrolides
  • Concurrent medication with ergotamine, theophylline, digitalis
  • Inability to swallow tablets
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04369365


Locations
Layout table for location information
Austria
AKH Vienna, Department for Internal Medicine I, Oncology
Vienna, Austria, 1090
Sponsors and Collaborators
Prof. Dr. Matthias Preusser
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Prof. Dr. Matthias Preusser, Prof. Dr., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT04369365    
Other Study ID Numbers: OnCoVID-19 Trial
First Posted: April 30, 2020    Key Record Dates
Last Update Posted: April 7, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
Coronavirus Infections
COVID-19
Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Respiratory Tract Infections
 Pneumonia, Viral
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Azithromycin
Anti-Bacterial Agents
Anti-Infective Agents